Does Tigecycline Raise AST Levels?
Tigecycline, an intravenous glycylcycline antibiotic used for complicated skin infections and intra-abdominal infections, commonly elevates liver enzymes including AST (aspartate aminotransferase). Clinical trials show AST increases in 15-30% of patients, typically mild to moderate (up to 3-5 times upper limit of normal), resolving after treatment ends.[1][2]
How Common Are AST Elevations and in What Patients?
In phase 3 trials (e.g., TEST program with over 5,000 patients), AST rose in 26% of tigecycline-treated adults versus 19% on comparators like vancomycin. Higher rates occur in those with baseline liver issues, obesity, or concurrent hepatotoxins. Children under 8 show similar patterns, around 10-20% incidence.[3][4] No direct dose-response link, but longer infusions (over 30 minutes recommended) may reduce peaks.
What Mechanisms Cause These Changes?
Tigecycline inhibits bacterial protein synthesis but induces mitochondrial dysfunction in hepatocytes, boosting reactive oxygen species and impairing AST metabolism. It also disrupts bile acid transport, mimicking cholestatic injury. Elevations peak 3-7 days into therapy, often with ALT rises (more frequent at 30%).[5]
Are Tigecycline-Induced AST Changes Dangerous?
Most cases are asymptomatic and reversible within 7-14 days post-treatment; severe (>10x ULN) or persistent elevations are rare (<2%), but linked to acute liver injury in case reports, especially with biliary obstruction or alcohol use. Monitor AST weekly; discontinue if >5x ULN with symptoms like jaundice.[1][6]
How Does Tigecycline Compare to Other Antibiotics on Liver Enzymes?
Tigecycline causes more AST/ALT rises than beta-lactams (e.g., piperacillin-tazobactam, 10-15%) but similar to linezolid or vancomycin. Versus tetracyclines like doxycycline, tigecycline is worse due to higher biliary excretion (50% unchanged).[3][7] In polymicrobial infections, adding tigecycline ups risk 1.5-2x.
When Should Doctors Avoid Tigecycline for AST Concerns?
Contraindicated in severe hepatic impairment (Child-Pugh C); dose-adjust for moderate (Child-Pugh B). Baseline AST >2.5x ULN warrants alternatives like meropenem. FDA label flags hepatotoxicity; EU data notes 1-2% hypersensitivity-related spikes.[1][4]
[1]: FDA Tigecycline Label
[2]: Tygacil Prescribing Information
[3]: TEST Clinical Trials Summary
[4]: EMA Tigecycline Assessment
[5]: Hepatotoxicity Review
[6]: LiverTox Database: Tigecycline
[7]: Antibiotic Liver Injury Comparison